Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet

Abstract : Foscarnet is currently licensed for the treatment of human cytomegalovirus (HCMV) infection. Mutations proven to confer resistance to foscarnet have mostly been mapped to regions II, III and VI of the HCMV UL54-encoded DNA polymerase. We previously showed that sequential foscarnet-resistant HCMV isolates recovered from a patient with lymphoma had change N495K in region delta-C of the DNA polymerase. To evaluate the impact of change N495K on HCMV sensitivity to foscarnet, a recombinant HCMV strain carrying the mutation was produced by homologous recombination. The recombinant virus showed a 3.4-fold increase in foscarnet resistance, and remained sensitive to ganciclovir and cidofovir. In addition, the recombinant strain showed a reduction of infectious virus yield compared with its parent strain. Change N495K should be added to the list of mutations conferring resistance to foscarnet and be taken into account in the genotypic diagnosis of antiviral resistance.
Liste complète des métadonnées

https://hal-unilim.archives-ouvertes.fr/hal-00405899
Contributeur : Ingrid Bucek <>
Soumis le : mardi 21 juillet 2009 - 11:54:43
Dernière modification le : mercredi 19 août 2020 - 11:16:28

Identifiants

  • HAL Id : hal-00405899, version 1
  • PUBMED : 16856628

Citation

Alexandra Ducancelle, Gaël Champier, Sophie Alain, Françoise Petit, Marie-José Sanson Le Pors, et al.. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. Antiviral Therapy, International Medical Press, 2006, 11 (4), pp.537-540. ⟨hal-00405899⟩

Partager

Métriques

Consultations de la notice

221